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aposi’s sarcoma-associated herpesvirus encodes
two transmembrane proteins (modulator of immune
 
recognition [MIR]1 and MIR2) that downregulate cell
surface molecules (MHC-I, B7.2, and ICAM-1) involved in the
immune recognition of infected cells. This downregulation
results from enhanced endocytosis and subsequent endoly-
sosomal degradation of the target proteins. Here, we show
that expression of MIR1 and MIR2 leads to ubiquitination
of the cytosolic tail of their target proteins and that ubiquit-
ination is essential for their removal from the cell surface.
K
 
MIR1 and MIR2 both contain cytosolic zinc ﬁngers of the
PHD subfamily, and these structures are required for this
 
activity. In vitro, addition of a MIR2–glutathione 
 
S
 
-transferase
(GST) fusion protein to puriﬁed E1 and E2 enzymes leads to
transfer of ubiquitin (Ub) to GST-containing targets in an
ATP- and E2-dependent fashion; this reaction is abolished
by mutation of the Zn-coordinating residues of the PHD
domain. Thus, MIR2 deﬁnes a novel class of membrane-
bound E3 Ub ligases that modulates the trafﬁcking of host
cell membrane proteins.
 
Introduction
 
Viruses of the herpesvirus family are important human
pathogens that produce a wide variety of disease states
linked to persistent infection of the host. Although many
factors underlie viral persistence, one important contributor
is thought to be the elaboration of virally encoded molecules
that promote evasion of host cell–mediated immunity
(Ploegh, 1998). Elegant studies of cytomegalovirus (Wiertz
et al., 1997; Hengel et al., 1998), HSV-1 (York et al.,
1994), and MHV-68 (Hengel et al., 1999) infection have
revealed that such proteins typically target host MHC
class I (MHC-I) polypeptides and lead to downregulation
of their surface display, thereby impairing recognition of
infected cells by host cytotoxic T lymphocytes. The several
viral proteins involved in this activity employ different
mechanisms to accomplish this task. Some impair the
function of the peptide transporter (TAP) that allows the
charging of assembling MHC-I chains with antigenic peptides
(Fruh et al., 1995), whereas others lead to retention of
newly made MHC-I chains in the ER (Ahn et al., 1996;
Jones et al., 1996), their relocation to the cytosol for pro-
teosomal degradation (Wiertz et al., 1996), or their traf-
ficking to the lysosome during export (Reusch et al.,
1999).
Kaposi’s sarcoma-associated herpesvirus (KSHV)* (also
called human herpesvirus 8) is a lymphotropic herpesvirus
that is strongly implicated in the pathogenesis of Kaposi’s
sarcoma and two AIDS-related lymphoproliferative syndromes
(Whitby and Boshoff, 1998). We (Coscoy and Ganem,
2000, 2001) and others (Ishido et al., 2000a,b) have shown
recently that the viral genome contains two genes, K3 and
K5, that encode transmembrane proteins (now named
modulator of immune recognition [MIR]1 and MIR2)
that are involved in the downregulation of MHC-I and
other molecules (B7.2 and ICAM-1) involved in immune
recognition (see below). The pathway of this downregula-
tion is novel: the target proteins are synthesized efficiently
and assembled in the endoplasmic reticulum, acquire their
 
N-linked glycans with normal kinetics, and reach the cell surface
normally. However, from that locale they are endocytosed
rapidly and efficiently, as judged both morphologically and
by the fact that blockade of endocytosis with dominant negative
mutants of dynamin restores surface expression of the chains
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(Coscoy and Ganem, 2000, 2001). Once internalized, the
chains are subsequently degraded in the endolysosomal com-
partment, a reaction that is blocked by chloroquine, ammo-
nium chloride, and other inhibitors of endolysosomal acidi-
fication (Coscoy and Ganem, 2000).
MIR1 and MIR2 are type III transmembrane proteins
whose NH
 
2
 
- and COOH-terminal regions project into the
cytosol (unpublished data). The NH
 
2
 
-terminal region of
both proteins harbors a Zn finger of the PHD/LAP subfam-
ily (Nicholas et al., 1997). This domain is essential for
MHC-I downregulation, as is a second cytosolic element lo-
cated in the COOH-terminal domain (unpublished data).
Although the overall pathway in which they function is now
clear, MIR1 and MIR2 have slightly different target specific-
ities (see below), and the molecular mechanisms by which
they act have therefore been obscure. Here, we show that an
important target for MIR2-mediated downregulation resides
in the cytosolic tail of the B7.2 molecule. By mapping of the
target residues, we uncovered that lysine residues in the tail
are critical for MIR2-mediated regulation and that this pro-
cess is tightly linked to ubiquitination of these residues. In
vitro experiments indicate that the NH
 
2
 
-terminal region of
MIR2 can direct the ubiquitination of a substrate protein in
the presence of purified functional E1 and E2 enzymes.
These results indicate that MIR2 is the prototype of a new
family of membrane-bound E3 Ub ligases whose activity in-
fluences the trafficking of host cell membrane proteins.
 
Results
 
Mapping the determinants of MIR action on 
its B7 target
 
To better understand the mechanisms of MIR-mediated
regulation, we mapped the determinants on the target host
protein that are required for this regulation. For this pur-
pose, we took advantage of the fact that MIR2 can downreg-
ulate the cell surface protein B7.2 (Ishido et al., 2000a;
Coscoy and Ganem, 2001) (a costimulatory molecule im-
portant in T cell activation) but not its closely related homo-
logue B7.1 (Fig. 1 A). (Interestingly, neither protein can be
efficiently downregulated by MIR1 [Fig. 1 A; Ishido et al.,
2000a; Coscoy and Ganem, 2001].) Accordingly, we con-
structed chimeras between B7.1 and B7.2 and tested their
ability to be downregulated by MIR2 expression (Fig. 1 B).
HeLa cells were stably transduced with each of the B7.1/
B7.2 chimeras diagrammed in Fig. 1 B. These chimeras were
Figure 1. The intracytoplasmic 
region of B7.2 is required for MIR2-
mediated downregulation. (A) BJAB 
cells were stably transduced with 
PMX-pie (the control vector), 
pBP-MIR1/EGFP, or pBP-MIR2/EGFP–
derived retroviral vectors. Cell surface 
expression of B7.1 and B7.2 was 
monitored by flow cytometry. (B, left) 
Schematic representation of chimeras 
between B7.1 and B7.2. (B, right) HeLa 
cells stably expressing the indicated 
chimeric proteins were stably 
transduced a second time with either 
PMX-pie, pBP-MIR1/EGFP, or 
pBP-MIR2/EGFP. Surface expression 
of the chimeric proteins was analyzed 
by flow cytometry. Presence or absence 
of downregulation is indicated 
respectively as   or  . 
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found to be stable and were expressed at normal levels on the
cell surface in the absence of MIR2 (unpublished data).
Next, HeLa cell expressing each of these chimeras were sta-
bly transduced a second time with either an empty vector
(pMX-pie) or an expression vector for MIR1 or MIR2 (here
expressed as functional GFP fusion proteins with plasmids
pB-MIR1/EGFP and pB-MIR2/EGFP, respectively) and
levels of the chimera on the cell surface measured by flow cy-
tometry. As summarized in Fig. 1 B, the ability of the chi-
meras to be downregulated by MIR2 mapped uniquely to
the cytosolic tail of B7.2, which was both necessary and suf-
ficient to confer downregulation. Interestingly, several of the
chimeras acquired the ability to be downregulated by MIR1,
a fact to which we shall return in the Discussion.
For higher resolution mapping of the target sequences,
we introduced deletions into the cytosolic tail of B7.2 and
examined their effects on MIR2-mediated downregulation.
Fig. 2 A depicts the deletions employed; as shown in Fig. 2
B, all deletion mutants were stably expressed on the cell
surface at normal levels in the absence of MIR2 (pMX-pie
control). In the presence of MIR2, mutant B7.2
 
 
 
1 was
strongly downregulated, but mutant B7.2
 
 
 
2 was com-
pletely unaffected. Examination of the amino acid se-
quence of the two mutants revealed the presence of a
lysine-rich segment that is present in B7.2
 
 
 
1 but absent in
B7.2
 
 
 
2. Interestingly, mutation of these four contiguous
lysine residues to alanine in the context of the intact cyto-
solic tail (mutant B7.2-7A) did not abolish MIR2-medi-
ated endocytosis (Fig. 2 B). This indicates that there are
likely to be multiple redundant signals in the cytosolic tail;
in this connection, we note that B7.2-7A retains seven ad-
ditional lysines in its intracytoplasmic domain.
To better define the contribution of lysine residues to
MIR2-mediated endocytosis, we examined the regulation of
the class I MHC allele HLA-B7 whose cytosolic tail harbors
only two lysines (at positions 332 and 337). Each of these was
singly mutated to arginine (to minimize changes in charge or
basicity); in addition, we constructed the corresponding dou-
ble mutant. Each construct was first transduced into BJAB
cells; the resulting neomycin-resistant cell population was
then transduced a second time with either pMX-pie (vector
control) or pB-MIR2/EGFP, a vector expressing a functional
MIR2-GFP fusion protein. 2 d later, cells were examined by
flow cytometry for GFP and surface MHC-I expression. As
shown in Fig. 3, cells expressing MIR2-GFP strongly down-
regulated surface expression of wild-type (wt) MHC-I and
each of the single lys/arg mutants; however, the double mu-
tant was completely refractory to MIR2 regulation
 
MIR2 expression results in ubiquitination of its targets
 
In contemplating what functions of lysine might not be sup-
ported by an identically positioned arginine residue, it oc-
curred to us that post-translational modification by Ub
(Pickart, 2001) (or by Ub-like modifiers [Melchior, 2000])
might behave in this fashion. Although ubiquitination is
most widely recognized as a strategy for targeting proteins
for degradation in cytosolic proteosomes, recent studies in-
dicate that this modification can serve other functions in
both yeast and mammalian cells (Hicke, 2001b). Particu-
larly relevant are recent reports that certain mammalian cell
Figure 2. A small motif within B7.2 intracyto-
plasmic region is required for MIR2-mediated 
downregulation. HeLa cells stably expressing 
truncation mutants of B7.2 (indicated in A) were 
transduced a second time by either PMX-pie or 
pBP-MIR2/EGFP. Cell surface expression of the 
indicated B7.2 constructs was analyzed by flow 
cytometry (B). 
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surface receptors that are known to undergo ligand-medi-
ated downregulation (e.g., those for EGF and human
growth hormone) are ubiquitinated on their cytosolic tails
during this process, and strong evidence indicates that this
modification is required for receptor downregulation (Lee et
al., 1999; de Melker et al., 2001). In many of these cases, the
cytosolic RING finger–containing protein cbl has been im-
plicated as the likely E3 Ub ligase that catalyzes the transfer
of Ub to the receptor (Waterman et al., 1999).
Accordingly, we looked for evidence that B7.2 and MHC-I
chains might undergo ubiquitination in the presence of MIR
proteins. HeLa cells stably expressing B7.2 were transduced
with pMX-pie, pB-MIR1/EGFP, or pB-MIR2/EGFP. After
puromycin selection, chains were immune precipitated with
anti-B7.2 antibody, and the resulting precipitates were frac-
tionated by SDS-PAGE, transferred to membranes, and blot-
ted with anti-Ub antibody. As shown in Fig. 4 (right), no
ubiquitinated forms were observed in vector or MIR-1–
expressing cells. However, in MIR2-expressing cells, ubiquiti-
nation of B7.2 chains was readily detectable, producing a
characteristic heterogeneous array that is presumably due to
either polyubiquitin addition, ubiquitination of multiple tar-
get lysines, or both. Similarly (Fig. 4, left), cells expressing ei-
ther MIR1 or MIR2 display ubiquitination of their endoge-
nous MHC-I chains, whereas such chains are not detected in
control cells lacking expression of either MIR1 or MIR2.
These results demonstrate a striking correlation between
the presence of cytosolic lysines, ubiquitination of the cyto-
solic tail, and the ability to be endocytosed. They reveal that
such lysines are necessary for MIR-induced endocytosis but
do not establish that they are sufficient for this activity. To
examine this question, we created by mutation a stretch of
three contiguous lysine residues in the cytoplasmic tail of
B7.1, which normally has no lysines in its intracytoplasmic
Figure 3. The presence of lysines in the MHC-I intracytoplasmic 
region is required for MIR2-mediated downregulation. Lysine 332 
and/or lysine 337 within the HLA.B7 cytoplasmic region were 
mutated to arginine, and the resulting constructs was stably expressed 
in BJAB cells. Cells were then transiently transduced a second time 
with either the control vector pMX-pie or pB-MIR2/EGFP, a vector 
expressing a functional MIR2–GFP fusion protein. Cell surface 
expression of HLA.B7 wt or mutant molecules was analyzed by 
flow cytometry.
Figure 4. MIR1 and MIR2 mediate ubiquitination of their targets. 
wt HeLa cells or HeLa cells expressing B7.2 were stably transduced 
by pMX-pie, pBP-MIR1/EGFP, or pBP-MIR2/EGFP. B7.2 molecules 
(right) or MHC-I molecules (left) were immunoprecipitated, and 
their ubiquitination status was determined by Western blot analysis 
using an anti-Ub antibody.
Figure 5. Addition of lysine into B7.1 enable its downregulation. 
(A) Sequence of the TM and intracytoplasmic regions of B7.1 (top 
line) and B7.1KKK mutant (bottom line). The mutant residues within 
the cytoplasmic region of B7.1KKK are indicated in boldface. (B) 
B7.1 wt and KKK mutant constructs were stably expressed in HeLa 
cells. Cells were transduced a second time by pBP-MIR2/EGFP, and 
surface expression of the B7.1 molecules was analyzed by flow 
cytometry. (C) Cells expressing B7.1 wt or KKK mutant proteins 
were stably transduced by pMX-pie, pBP-MIR1/EGFP, or 
pBP-MIR2/EGFP. From each set of transductants, B7.1 molecules 
were immunoprecipitated and analyzed by Western blot using an 
anti-Ub antibody. 
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domain and is not endocytosed in response to MIR2 expres-
sion (Fig. 5 A). When expressed in cells bearing functional
MIR2, the wt molecule is present at readily detectable levels
on the cell surface, but the mutant displays clear downregu-
lation (Fig. 5 B). As expected, when the B7.1 KKK mutant
was immunoprecipitated with anti-B7.1 and blotted with
anti-Ub, ubiquitinated forms of the protein were readily de-
tected, whereas no ubiquitination of wt B7.1 was observed
(Fig. 5 C).
How does MIR protein expression lead to ubiquitination
of its target MHC or B7 molecules? Ubiquitination is a
modification performed by a cascade of cytosolic enzymes.
So-called E1 (Ub-activating) enzymes activate Ub in an
ATP-dependent reaction that couples Ub to the E1 active
site cysteine via a thioester bond. The Ub moiety is then
transferred to a second protein, the E2 (Ub-conjugating) en-
zyme. The final step is the transfer of the Ub to the 
 
 
 
-amino
group of the substrate lysine. This reaction rarely proceeds
directly; typically, it requires catalysis by a third class of en-
zymes, the E3 Ub ligases. These proteins bind both the E2
and the target, promoting a complex that brings the E2 and
the substrate into proximity. Interestingly, MIR proteins
contain Zn fingers of the PHD family, structural motifs
thought to be involved in protein–protein interactions
(Linder et al., 2000; Pascual et al., 2000; Yochum and Ayer,
2001). Our previous work has shown that these variant Zn
fingers are located in the NH
 
2
 
-terminal cytoplasmic domain
of the protein (Coscoy and Ganem, 2000) and so would be
available for E2 interactions. Moreover, mutations that
disrupt the PHD/Zn finger domain ablate MIR-induced
MHC downregulation (Ishido et al., 2000a; unpublished
data). So the simplest model is that MIRs might serve as E3
Ub ligases that direct the E2 Ub-conjugating enzymes to
MHC-I and B7-2, much as cbl directs E2s to the cytosolic
tails of activated growth factor receptors. This is a particu-
larly attractive model, since the PHD family of Zn fingers
are very closely related structurally to the RING fingers
(Capili et al., 2001) found in many cytosolic E3s (e.g., cbl).
Accordingly, we tested the ability of wt and PHD mutant
forms of MIR2 to functionally interact with a series of
known eukaryotic E2 Ub-conjugating enzymes. In one stan-
dard assay of such interaction, in vitro incubation of glu-
tathione 
 
S
 
-transferase (GST)–E3 fusions bearing the RING
finger region with active E1 and E2 enzymes leads to trans-
fer of Ub to the GST region of the fusion protein (Joazeiro
et al., 1999). To see if MIR2 could function in such an as-
say, we fused the NH
 
2
 
-terminal cytosolic region of MIR2
(bearing its PHD domain) to GST and expressed the result-
ing fusion protein in 
 
Escherichia coli
 
. In parallel, a MIR2–
GST fusion bearing mutations in key cysteine residues of the
PHD/Zn finger was expressed. Both proteins were partially
purified by binding to glutathione-Sepharose (GS), and
equal amounts of each was added to a reaction mix contain-
ing ATP, Ub, purified E1, and the human E2 UbcH5a. Af-
ter incubation, the resulting GST-containing protein prod-
ucts were purified by GS binding, separated by SDS-PAGE,
transferred to filters, and probed with anti-Ub antibody. As
shown in Fig. 6, in the presence of the wt MIR2–GST fu-
sion a prominent band of high molecular weight products
reactive with anti-Ub was observed; these products were not
detected in reactions programmed with GST alone or with
the MIR2–GST fusion protein bearing point mutations in
the PHD domain. As expected, these ubiquitinated reaction
products were dependent on the presence of ATP and E2
enzyme (Fig. 6).
 
The transmembrane (TM) region of the target protein 
plays a role in the MIR2-mediated target selection
 
The results presented thus far have focused upon the role of
the cytosolic tail of the target protein in MIR-mediated reg-
ulation, and this role that can now be understood in terms
of the provision of substrate lysines for ubiquitination by
E2s recruited by MIR2’s PHD domain. However, interac-
tion with E2s is only one function of an E3. Another key
role an E3 must play is target recognition, and in most E3s
this function is subsumed by a different domain than that
involved in E2 recruitment. We have found recently that the
TM domains of MIR2 contribute critically to target selectiv-
ity (unpublished data). To better understand which regions
of the target might contribute to MIR recognition, we took
advantage of the fact that MIR2 can downregulate human
but not murine MHC-I chains, even when the latter are ex-
pressed in a human cell (Fig. 7 A; Stevenson et al., 2000).
Since both human and mouse MHC-I proteins contain cy-
tosolic lysines, this suggests that the failure of MIR2 to regu-
late mouse MHC-I might reside at the level of target recog-
nition. To further understand this issue, we constructed
chimeras between mouse MHC-I (H2 Dd) and human
MHC-I (HLA.B7) and tested their ability to be regulated by
MIR2. BJAB cells stably expressing MIR2 or vector alone
were transiently transfected with an expression vector for wt
HLA B7 (which is not expressed endogenously by BJAB
cells). All transfections proceeded with comparable effi-
Figure 6. The MIR2 PHD domain can mediate ATP/E2-dependent 
ubiquitination in vitro. In vitro ubiquitination reactions were 
performed as described in Materials and methods. In the complete 
reaction mix, 10  g of GS-bound GST, GST-MIR2 wt PHD domain, 
and GST-MIR2 mutant PHD domain were added to a cocktail of 10 
mM ATP, 2 mg Ub, 40 ng of E1, and 1  g of the E2 UbcH5a. In the 
remaining lanes, individual components of the full reaction mix 
were omitted as indicated above each lane. After the reaction, 
GS-bound material was recovered by centrifugation, eluted with 
SDS sample buffer, and examined by Western blotting with anti-Ub 
antibody. 
1270 The Journal of Cell Biology 
 
|
 
 
 
Volume 155, Number 7, 2001
 
ciency (unpublished data). As shown in Fig. 7 A, a 15-fold
decrease in the number of cells expressing HLA B7 was ob-
served in cells expressing MIR2 compared with cells express-
ing the control vector. As expected, mouse MHC-I chains
did not display this MIR2-mediated downregulation. Simi-
lar experiments were performed using the chimeras depicted
in Fig. 7 B. As shown in Fig. 7 B, chimera 3, containing the
TM and intracellular region of mouse MHC, cannot be
downregulated by MIR2. On the other hand, chimera 2,
which differs from chimera 3 principally in containing the
TM and juxtamembrane region of human MHC, is effi-
ciently downregulated by MIR2. This suggests that the TM
and juxtamembrane regions of the target MHC chains con-
tribute critically to recognition by MIR proteins.
 
Discussion
 
Our results establish that MIR-mediated downregulation of
the cell surface molecules involved in immune recognition is
mediated by ubiquitination of their cytosolic tails followed
by their endocytosis and subsequent lysosomal degradation.
The in vitro ability of MIR2’s PHD domain to promote a
Ub transfer reaction in an ATP- and E2-dependent fashion
strongly indicates that the MIR proteins participate in this
process by serving as E3 Ub ligases. The MIR proteins thus
represent a novel class of membrane-bound E3 enzymes and
are the first E3s to be found to be dependent on a Zn finger
of the PHD rather than the RING subfamily. In this con-
nection, it is of note that the first solution structure of a
PHD domain has been published recently and reveals a
striking structural relatedness to known RING fingers
(Capili et al., 2001).
Although ubiquitination is associated most prominently
with proteosome-mediated degradation, recent studies reveal
roles for this modification in a variety of other processes in
cell biology, including transcription factor function and
membrane protein trafficking (Hicke, 2001b). Clear evi-
dence links ubiquitination to the endocytosis of many pro-
teins in yeast. In mammalian cells, this modification has
been implicated in more specialized endocytic events, princi-
pally those involved in the ligand-induced downregulation
of several growth factor receptors (Hicke, 2001a). In that
setting, ubiquitination of the target is usually catalyzed by
the RING finger–containing E3 known as cbl, which is re-
cruited to the activated (tyrosine-phosphorylated) growth
factor receptors via its SH2 domain. Ubiquitination is also
Figure 7. A critical domain within the 
transmembrane region of human MHC-I 
is required for MIR2-mediated down-
regulation. (A) Cells stably expressing 
the control vector or MIR2 were 
transiently transfected with the human 
or the mouse MHC-I molecule (HLA.B7 
and H2 Dd, respectively). The number 
of cell expressing the transfected MHC-I 
at the surface was measured by flow 
cytometry. (B) Chimeric proteins 
between human (bold) and mouse 
(underlined) MHC-I were engineered, 
and their susceptibility to MIR2-mediated 
downregulation was analyzed as above. 
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implicated in the endocytosis of the epithelial sodium chan-
nel (Enac); however, in this case the responsible E3 (Nedd4)
is a member of the structurally unrelated HECT domain–
containing family of E3s (Staub et al., 1997). Our data re-
veal that ubiquitination can also regulate the endocytosis of
another class of cell surface targets, those involved in CTL
recognition and helper T cell activation, and raise the possi-
bility that this modification may be more widely involved in
regulating the trafficking of other classes of targets. Indeed,
although the initial identification of the MIR proteins was
based on screens for viral genes that affect immune recogni-
tion our finding that these proteins are actually E3 Ub li-
gases raises the question of whether they might function
more broadly in the regulation of other Ub-dependent pro-
cesses. Based upon this notion, searches for additional tar-
gets of MIR2-mediated ubiquitination are now underway.
In this connection, we note that a homologue of MIR1
has been discovered recently in a murine gammaherpesvirus,
MHV68 (Stevenson et al., 2000). Unlike the KSHV MIR
proteins, the MHV68 protein (called MK3) does not influ-
ence MHC-I endocytosis; rather, it functions to trigger
MHC-I degradation. While this paper was being prepared
for submission, a report appeared that revealed that this deg-
radation could be inhibited by inhibitors of the proteosome
and that in the presence of such inhibitors ubiquitinated
MHC chains accumulated (Boname and Stevenson, 2001).
In those studies, the authors could not detect interactions of
MK3 with known components of the ubiquitination ma-
chinery and thus were unable to determine if the effects of
MK3 on ubiquitination were direct or indirect. Our data
strongly suggest that MK3 functions to directly recruit an
E2 to murine MHC-I. How MHC chains ubiquitinated in
the ER under the influence of MK3 are degraded by the pro-
teosome remains to be clarified, but the process appears to
differ in some respects from the previously described disloca-
tion of MHC polypeptides from the ER to the cytosol medi-
ated by cytomegalovirus proteins US2 and US11. Perhaps
the process is initiated by digestion of the cytosolic tail of
MHC-I by the proteosome, triggering degradation of the re-
mainder of the chain by other proteolytic systems.
The findings of Boname and Stevenson (2001) on MK3
raise interesting questions concerning the diversity of mech-
anisms by which even related E3s can act. Ubiquitination by
MK3 functions to trigger proteosome-directed proteolysis,
whereas ubiquitination by the KSHV MIR proteins affects
endocytosis and endolysosomal degradation. As noted previ-
ously, both MK3 and the KSHV MIR proteins are localized
principally to the ER (Coscoy and Ganem, 2000; Steven-
son et al., 2000). Consistent with this localization, MK3-
directed degradation of MHC-I chains occurs predomi-
nantly in the ER. However, KSHV MIR1 and MIR2 do not
impair the assembly or transport of target chains in the ER
but exert their principal effects at the plasma membrane and
the endocytic pathway. How this comes about is uncertain,
but two possibilities can be envisioned. The first is that ER-
bound MIR chains might direct the ubiquitination of their
targets as they transit through the ER with the modified tar-
get proteins undergoing enhanced endocytosis once they
reach the surface. However, such a model is not in accor-
dance with our previous pulse–chase analyses, which show
that most chains exit the ER unmodified; moreover, MHC-I
chains made in the absence of MIR proteins can still be
downregulated after MIR expression (Coscoy and Ganem,
2000). Finally, the findings of Boname and Stevenson
(2001) indicate that if Ub were added to MHC-I in the ER,
the likely consequence would be degradation. For these rea-
sons, we favor the model that a small percentage of MIR
chains escape the ER and reach the plasma membrane where
they can serve their targeting function.
The basis of this targeting function has been illuminated
by experiments (Fig. 7; D. Sanchez et al, personal communi-
cation), implicating the TM and juxtamembrane regions of
both target and effector chains in target selection. Based on
these studies, we propose a model for how MIR-mediated
ubiquitination might proceed (Fig. 8). In this model, the
TM and juxtamembrane regions of MIR2 and its target
chains mediate an interaction in the plane of the membrane;
this juxtaposes the NH
 
2
 
-terminal PHD domain of MIR2
(with its associated E2) with the cytosolic tail of the target,
thereby facilitating ubiquitination of its substrate lysine resi-
dues. How ubiquitination of the target promotes its endocy-
tosis and endolysosomal degradation remains a matter for
further study. In other systems, ubiquitination is known to
affect both internalization and the delivery of endosomal
contents to lysosomes (for review see Hicke, 2001a). The
fact that coexpression of MIR2 with dynamin dominant
negative mutants leads to accumulation of cell surface
MHC-I (Coscoy and Ganem, 2000) suggests that MIR-
induced ubiquitination likely targets at least the internaliza-
tion step, but further work will be needed to determine if
downstream events are also influenced by MIR2.
The seemingly paradoxical finding (Fig. 1 B) that certain
chimeras between B7.1 and B7.2 can be downregulated by
MIR1 (which cannot downregulate either wt B7 species) can
Figure 8. A model for MIR2 function as an E3 Ub ligase. MIR2 TM 
domains mediate recognition of their target molecules TM regions 
in the plane of the membrane, whereas its cytosolic PHD domain 
recruits one or more E2 Ub-conjugating enzymes and brings them 
into proximity with the cytosolic tail of the target protein, facilitating 
the transfer of Ub to key lysine residues. 
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now be understood in terms of this model. Since wt B7.1
lacks cytosolic lysines (Fig. 5 A), it cannot be regulated by ei-
ther MIR1 or MIR2 (Fig. 1 B, lines 1 and 8). However, a
chimera containing only the TM region of B7.1 (Fig. 1 B,
line 3) can be regulated by both MIR proteins. This suggests
that both MIR1 and MIR2 can recognize the TM region of
B7.1; their failure to regulate wt B7.1 is based primarily on
their inability to ubiquitinate B7.1 cytoplasmic tail. The
failure of MIR1 to regulate a chimera with the TM and in-
tracytoplasmic regions of B7.2 indicates that the inability of
MIR1 to regulate wt B7.2 is due to its inability to recognize
the TM region of B7.2.
We do not yet know if MIR1 and MIR2 act alone or in
concert with other as yet unidentified partners to recruit the
ubiquitination machinery. However, the observation that
KSHV MIR2 is inactive in murine cells (unpublished data)
suggests that additional host proteins are likely involved in
MIR-mediated downregulation. This would not be surpris-
ing, since many E3s operate in large multisubunit complexes
(Jackson et al., 2000). Another reason to suspect roles for
other host proteins in MIR function derives from the compar-
ison of MK3 with MIR1 and MIR2. If ER-localized chains of
one member of this protein family (MK3) can mediate ubiq-
uitination of MHC-I in situ, why is this activity not observed
for other members of the family? One possibility is that, in the
case of the MIRs, host ER or cytosolic proteins may negatively
regulate their E3 activity in this organelle. Finally, it will be
important to clarify which of the many cellular E2s is/are the
natural ligand(s) of MIR2. Although UbcH5a was active in
the in vitro Ub transfer reaction orchestrated by MIR2’s PHD
domain, this result need not imply that this E2 is a true in
vivo ligand of MIR2. Indeed, preliminary yeast two-hybrid
analyses suggest that other E2s may be more likely candidates
for this role. The identification of these and other host com-
ponents that interact with MIR proteins should shed light on
the molecular details of the connection between ubiquitina-
tion and endocytosis and further our understanding of this
unusual pathway of immune evasion.
 
Materials and methods
 
Cell lines and cell culture
 
HeLa cells and Phoenix cells were grown in DME-H21 supplemented with
10% (vol/vol) FCS and penicillin streptomycin. BJAB lymphoma cells were
grown in RPMI 1640 supplemented as described above.
 
Antibodies
 
For FACS
 
®
 
 analysis, all antibodies were used at a concentration of 1 
 
 
 
g/10
 
6
 
cells. Anti-Ub monoclonal antibody (Santa Cruz Biotechnology, Inc.) was
used for Western blot at a dilution of 1/1,000. Purified monoclonal anti–
human HLA class I antigen (W6/32) was from Dako. Purified monoclonal
anti-B7.2 and PE-conjugated monoclonal anti–human HLA-B7 were from
Pharmingen. Monoclonal anti-B7.1 was provided by Lewis Lanier (Univer-
sity of California, San Francisco, CA).
 
Plasmids
 
B7.1, B7.2, H2 Dd, and HLA B7 cDNA clones were provided by Lewis
Lanier (University of California). All constructs were amplified by PCR am-
plification using these cDNAs and cloned into BamHI and SalI restriction
sites of pBMN-Zin (provided by G. Nolan, Stanford University, Palo Alto,
CA). Point mutations and chimeric fusions were made by amplification of
overlapping PCR fragments and cloned into the of pBMN-Zin with the ex-
ception of the MIR1–EGFP and MIR2–EGFP fusion molecules. These fu-
sions were cloned into pBP, a modified pBMN vector in which the gene
for neomycin phosphotransferase gene has been replaced by the puromy-
 
cin 
 
N
 
-acetyl-transferase gene. The retroviral vector PMX-pie has been pro-
vided by Lewis Lanier (University of California). This vector expresses
EGFP, and the puromycin 
 
N
 
-acetyl-transferase gene and was used as a
control for experiments involving pBP retroviral vectors.
The first 249 nucleotides of MIR2 (coding for the PHD domain) were
amplified by PCR using oligonucleotides containing additional EcoRI and
NotI sites. GST fusion proteins were created by cloning this PCR fragments
into the pGEX 4T-1 vector (Amersham Pharmacia Biotech). As a control, a
second vector was generated where MIR cysteine codons in position 56
and 59 were mutated to serine codons.
 
Retroviral infection
 
On transfection with the retroviral vectors (pBMN based, pBP based, or
pMX-pie), the Phoenix packaging cell line produces replication-defective
viral particles that can be used for stable expression in HeLa or BJAB cells.
Phoenix cells were transfected, and the virus-containing supernatant was
harvested 48 h after the transfection, filtered through a 0.45-
 
 
 
m filter, and
diluted with Polybrene (8 
 
 
 
g/ml final dilution). HeLa cells and BJAB cells
(in 6-well dishes) were infected by spin infection (800 
 
g
 
 for 2 h at 20
 
 
 
C) us-
ing 2 ml of viral supernatant. Selection of pBMN-transduced cells was
started 36 h after infection by adding 1 mg/ml of G418 for HeLa cells or
1.5 mg/ml of G418 for BJAB cells. Cells transduced with pMX-pie or pBP
vectors were selected in the presence of 1 
 
 
 
g/ml of puromycin.
 
Flow cytometry analysis
 
Adherent cells were detached using enzyme-free/PBS-based cell dissocia-
tion buffer (GIBCO BRL) according to the manufacturer’s instructions.
Cells were washed in PBS/1% BSA and incubated with specific mono-
clonal antibodies (1 
 
 
 
g/10
 
6
 
 cell) for 30 min at 4
 
 
 
C. Unconjugated bound
mouse antibodies were revealed by a R-phycoerythrin–conjugated goat
anti–mouse antibody. Cell surface fluorescence was analyzed with a Bec-
ton Dickinson FACScalibur
 
®
 
.
 
Immunoprecipitation and Western blotting
 
10-cm dishes of HeLa cells were scraped, and protein lysates were made
by resuspending in RIPA buffer (for B7.1 and B7.2 immunoprecipitation) or
in PBS with 1% NP-40 (for MHC-I immunoprecipitation). The lysates were
cleared of debris and incubated with 2 
 
 
 
g antibody for 1 h before addition
of protein A/G
 
 
 
 agarose beads (Santa Cruz Biotechnology, Inc.). Immuno-
precipitated proteins were separated on a polyacrylamide gel, transferred
to nitrocellulose, and Western blotted with mouse anti-Ub, and then incu-
bated with goat anti–mouse Ig HRP and visualized with Luminol (Santa
Cruz Biotechnology, Inc.).
 
Protein purification
 
GST fusions proteins were expressed in log-phase 
 
E. coli 
 
Top 10 (Invitro-
gen) induced with 2 mM isopropyl 
 
 
 
-
 
D
 
-thiogalactoside for 3 h at 37
 
 
 
C.
Bacterial pellets were resuspended in 5 ml lysis buffer (50 mM Tris, pH 8,
120 mM NaCl, 3 mg/ml lysozyme, and proteases inhibitor) and incubated
on ice for 15 min. Cells were then lysed by addition of NP-40 (1% final
concentration) and three freeze-thaw cycles. Lysates were clarified by cen-
trifugation (12,000 
 
g
 
 for 30 min) and stored at 
 
 
 
80
 
 
 
C. GST fusion proteins
were purified by incubating the lysates with GS followed by extensive
washing of the GS. Quantification of the fusion proteins was determined
by Bradford assay and Coomassie blue using BSA as standards.
 
In vitro ubiquitination assay
 
Ubiquitination assays, unless indicated, were performed for 90 min at
30
 
 
 
C in 50 
 
 
 
l of ubiquitination reaction buffer (50 mM Tris, pH 7.4, 2.5
mM MgCl
 
2
 
, 0.5 mM DTT, and 10 mM ATP) using 10 
 
 
 
g GS-bound GST fu-
sion proteins (see above), 40 ng Ub-activating enzyme E1 (Calbiochem), 2
 
 
 
g of His6 Ub (A.G. Scientific), and 1 
 
 
 
g of UbcH5a (A.G. Scientific). GS-
bound materials were purified by extensive washing before Western blot
analysis.
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